Effects of alvocidib and carboplatin on ovarian cancer cells in vitro

Experimental Oncology

Volumn 35, Issue 3, 2013, Pages 168-173

  Baumann, K H ^a   Kim, H ^a   Rinke, J ^a   Plaum, T ^a   Wagner, U ^a   Reinartz, S ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Alvocidib; Apoptosis; Carboplatin; Drug accumulation; Flavopiridol; Ovarian cancer

Indexed keywords

CARBOPLATIN; FLAVOPIRIDOL;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARBOPLATIN; CELL DIVISION; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; FLAVONOIDS; HUMANS; OVARIAN NEOPLASMS; PIPERIDINES;

EID: 84892154553     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Schmalfeldt B, du Bois A, Burges A, et al. Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO. Zentralbl Gynekol 2006; 128: 11-7
2. Tummala MK, McGuire WP. Recurrent ovarian cancer. Clin Adv Hematol Oncol 2005; 3: 723-36
3. Gonzalez-Martin AJ. Medical treatment of epithelial ovarian cancer. Expert Rev Anticancer Ther 2004; 4: 1125-43
4. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-96
5. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039-45
6. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-9
7. Gronlund B, Hogdall C, Hansen HH, Engelholm SA. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 2001; 83: 128-34.
8. Green H, Soderkvist P, Rosenberg P, et al. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006; 12: 854-9
9. Roberts D, Schick J, Conway S, et al. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 2005; 92: 1149-58
10. Stewart JJ, White JT, Yan X, et al. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics 2006; 5: 433-43
11. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770-83
12. Mayer F, Mueller S, Malenke E, et al. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines. Invest New Drugs 2005; 23: 205-11
13. Yu C, Rahmani M, Dai Y, et al. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res 2003; 63: 1822-33.
14. Newcomb EW. Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs 2004; 15: 411-9.
15. Raju U, Nakata E, Mason KA, et al. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res 2003; 63: 3263-7
16. Song Y, Shen K, Tang PP. Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma. Zhonghua Fu Chan Ke Za Zhi 2007; 42: 761-4
17. Bible KC, Lensing JL, Nelson SA, et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005; 11: 5935-41
18. El-Rayes BF, Gadgeel S, Parchment R, et al. A phase I study of flavopiridol and docetaxel. Invest New Drugs 2006; 24: 305-10
19. Leonessa F, Jacobson M, Boyle B, et al. Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies. Cancer Res 1994; 54: 441-7
20. Tallarida RJ. The interaction index: a measure of drug synergism. Pain 2002; 98: 163-8
21. Canitrot Y, Lautier D. Use of rhodamine 123 for the detection of multidrug resistance. Bull Cancer 1995; 82: 687-97
22. Twentyman PR, Rhodes T, Rayner S. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer 1994; 30A: 1360-9
23. Hu K, Morris ME. Effects of benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport. J Pharm Sci 2004; 93: 1901-11
24. Baird RD, Kaye SB. Drug resistance reversal - are we getting closer? Eur J Cancer 2003; 39: 2450-61
25. Petru E, Sevin BU, Perras J, et al. Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence. Gynecol Oncol 1990; 38: 155-60
26. Bible KC, Boerner SA, Kirkland K, et al. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Clin Cancer Res 2000; 6: 661-70
27. Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res 2004; 64: 3653-60
28. Ali S, El-Rayes BF, Aranha O, et al. Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. Breast Cancer Res Treat 2005; 90: 25-31
29. Motwani M, Rizzo C, Sirotnak F, et al. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2003; 2: 549-55
30. Jiang J, Matranga CB, Cai D, et al. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Cancer Res 2003; 63: 7410-22
31. Melillo G, Sausville EA, Cloud K, et al. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 1999; 59: 5433-7.
32. Nguyen HN, Sevin BU, Averette HE, et al. Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines. Cancer Invest 1993; 11: 264-75
33. Li L, Luan Y, Wang G, et al. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma. Int J Mol Med 2004; 14: 257-64
34. Hille S, Rein DT, Riffelmann M, et al. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer. Anticancer Drugs 2006; 17: 1041-4
35. Yakirevich E, Sabo E, Naroditsky I, et al. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol Oncol 2006; 100: 152-9
36. Krasznai ZT, Friedlander E, Nagy A, et al. Quantitative and functional assay of MDR1/P170-mediated MDR in ascites cells of patients with ovarian cancer. Anticancer Res 2005; 25: 1187-92
37. Puhlmann U, Ziemann C, Ruedell G, et al. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J Pharmacol Exp Ther 2005; 312: 346-54
38. Ihnat MA, Nervi AM, Anthony SP, et al. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice. Oncol Res 1999; 11: 303-10
39. Lee JJ,Swain SM. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol 2005; 32: S22-6
40. Bible KC, Peethambaram PP, Oberg AL, et al. A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecol Oncol 2012; 127: 55-62